Gastrointestinal cancers: Influence of gut microbiota, probiotics and prebiotics

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 258-270

  Serban, Daniela Elena ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Dysbiosis; Gastrointestinal cancer; Gut microflora; Prebiotics; Probiotics

Indexed keywords

PLACEBO; POLYAMINE; PREBIOTIC AGENT; PROBIOTIC AGENT;

ACTINOBACTERIA; AGE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTEROIDETES; BIOSYNTHESIS; CANCER CELL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; DIETARY INTAKE; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DISEASE COURSE; DYSBIOSIS; EPIGENETICS; FIRMICUTES; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; METABOLOMICS; MICROBIAL ACTIVITY; NONHUMAN; PHYSICAL CHEMISTRY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEOBACTERIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SPECIES COMPOSITION;

ANIMALIA;

DYSBIOSIS; GASTROINTESTINAL CANCER; GUT MICROFLORA; PREBIOTICS; PROBIOTICS;

ANIMALS; DYSBIOSIS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTESTINES; PREBIOTICS; PROBIOTICS; TREATMENT OUTCOME;

EID: 84896714016     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.013     Document Type: Review

References (197)

1. Bazuro G.E., Torino F., Gasparini G., Capurso L. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?. Minerva. Gastroenterol. Dietol. 2009, 54:429-444.
2. Thiel A., Ristimäki A. Gastric cancer: basic aspects. Helicobacter 2012, 17:26-29.
3. Correa P., Piazuelo M.B. Evolutionary history of the Helicobacter pylori genome: implications for gastric carcinogenesis. Gut. Liver. 2012, 1:21-28.
4. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers and D.M. Parkin, Estimates of worldwide burden of cancer in 2008 GLOBOCAN 2008, Int. J. Cancer.127, 2010, 2893-2917.
5. Orlando A., Russo F. Intestinal microbiota, probiotics and human gastrointestinal cancers. J. Gastrointest. Cancer. 2013, 44:121-131.
6. Schottenfeld D., Beebe-Dimmer J.L., Vigneau F.D. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann. Epidemiol. 2009, 19:58-69.
7. Zhang M.M., Cheng J.Q., Xia L., Lu Y.R., Wu X.T. Monitoring intestinal microbiota profile: a promising method for the ultraearly detection of colorectal cancer. Med. Hypotheses. 2011, 76:670-672.
8. Sharma R., Young C., Mshvildadze M., Neu J. Intestinal microbiota: does it play a role in diseases of the neonate?. Neoreviews 2009, 10:166-179.
9. Serban D.E. The gut microbiota in the metagenomics era: sometimes a friend, sometimes a foe. Roum. Arch. Microbiol. Immunol. 2011, 70:134-140.
10. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., Mende D.R., Li J., Xu J., Li S., Li D., Cao J., Wang B., Liang H., Zheng H., Xie Y., Tap J., Lepage P., Bertalan M., Batto J.M., Hansen T., Le Paslier D., Linneberg A., Nielsen H.B., Pelletier E., Renault P., Sicheritz-Ponten T., Turner K., Zhu H., Yu C., Li S., Jian M., Zhou Y., Li Y., Zhang X., Li S., Qin N., Yang H., Wang J., Brunak S., Doré J., Guarner F., Kristiansen K., Pedersen O., Parkhill J., Weissenbach J., Consortium Meta H.I.T., Bork P., Ehrlich S.D., Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
11. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell. Host. Microbe. 2008, 3:417-427.
12. Tap J., Mondot S., Levenez F., Pelletier E., Caron C., Furet J.P., Ugarte E., Muñoz-Tamayo R., Paslier D.L., Nalin R., Dore J., Leclerc M. Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 2009, 11:2574-2584.
13. Bibiloni R., Membrez M., Chou C.J. Gut microbiota, obesity and diabetes. Ann. Nestlé. (Engl.) 2009, 67:39-47.
14. McConnell E.L., Fadda H.M., Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008, 364:213-226.
15. O'Hara A.M., Shanahan F. The gut flora as a forgotten organ. EMBO. Rep. 2006, 7:688-693.
16. Bordonaro M., Lazarova D.L., Sartorelli A.C. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk?. Cell. Cycle. 2008, 7:1178-1183.
17. Dronamraju S.S., Coxhead J.M., Kelly S.B., Mathers J.C. Differential antineoplastic effects of butyrate in cells with and without a functioning DNA mismatch repair. Nutr. Cancer 2010, 62:105-115.
18. Domokos M., Jakus J., Szeker K., Csizinszky R., Csiko G., Neogrady Z., Csordas A., Galfi P. Butyrate-induced cell death and differentiation are associated with distinct patterns of ROS in HT29-derived human colon cancer cells. Dig. Dis. Sci. 2010, 55:920-930.
19. Scharlau D., Borowicki A., Habermann N., Hofmann T., Klenow S., Miene C., Munjal U., Stein K., Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fiber. Mutat. Res. 2009, 682:39-53.
20. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133:2485S-2493S.
21. Blaser M.J. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev. Res. (Phila) 2008, 1:308-311.
22. Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev. Res. 2008, 1:329-338.
23. Brigic E., Hadzic D., Mladina N. Childhood and Correa model of carcinogenesis. Med. Arh. 2012, 6:375-377.
24. Pan S.Y., Morrison H. Epidemiology of cancer of the small intestine. World J. Gastrointest. Oncol. 2011, 3:33-42.
25. Thomas L.V., Ockhuizen T. New insights into the impact of the intestinal microbiota on health and disease: a symposium report. Br. J. Nutr. 2012, 107:S1-S13.
26. Rowland I.R. The role of the gastrointestinal microflora in colorectal cancer. Curr. Pharm. Des. 2009, 15:1524-1527.
27. Rafter J.J., Child P., Anderson A.M., Alder R., Eng V., Bruce W.R. Cellular toxicity of fecal water depends on diet. Am. J. Clin. Nutr. 1987, 45:559-563.
28. de Kok T., Van Faassen A., Glinghammar B., Pachen D., Rafter J.J., Baeten C., Engels L., Kleinjans J.C. Bile acid concentrations, cytotoxicity, and pH of fecal water from patients with colorectal adenomas. Dig. Dis. Sci. 1999, 44:2218-2225.
29. Venturi M., Hambly R.J., Glinghammar B., Rafter J.J., Rowland I.R. Genotoxic activity in human faecal water and the role of bile acids: A study using the Comet assay. Carcinogenesis 1997, 18:2353-2359.
30. Vannucci L., Stepankova R., Kozakova H., Fiserova A., Rossmann P., Tlaskalova-Hogenova H. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int. J. Oncol. 2008, 32:609-617.
31. Kado S., Uchida K., Funabashi H. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor chain and p53 double-knockout mice. Cancer Res. 2001, 61:2395-2398.
32. Uronis J.M., Muhlbauer M., Herfarth H.H., Rubinas T.C., Jones G.S., Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009, 4:e6026.
33. Marchesi J.R., Dutilh B.E., Hall N., Peters W.H., Roelofs R., Boleij A., Tjalsma H. Towards the human colorectal cancer microbiome. PLoS One 2011, 6:e20447.
34. Prakash S., Rodes L., Coussa-Charley M., Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011, 5:71-86.
35. Hawrelak J.A., Myers S.P. The causes of intestinal dysbiosis: a review. Altern. Med. Rev. 2004, 9:180-197.
36. Wang Z.K., Yang Y.S. Upper gastrointestinal microbiota and digestive diseases. World J. Gastroenterol. 2013, 19:1541-1550.
37. Blackett K.L., Siddhi S.S., Cleary S., Steed H., Miller M.H., Macfarlane S., Macfarlane G.T., Dillon J.F. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?. Aliment. Pharmacol. Ther. 2013, 37:1084-1092.
38. Diakowska D., Markocka-Maczka K., Grabowski K., Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp. Oncol. 2006, 28:319-322.
39. Dicksved J., Lindberg M., Rosenquist M., Enroth H., Jansson J.K., Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 2009, 58:509-516.
40. Engstrand L., Lindberg M. Helicobacter pylori and the gastric microbiota. Best. Pract. Res. Clin. Gastroenterol. 2013, 27:39-45.
41. Piscaglia A.C., Campanale M., Gasbarrini G. Small bowel nonendocrine neoplasms: current concepts and novel perspectives. Eur. Rev. Med. Pharmacol. Sci. 2010, 14:320-326.
42. Horie H., Kanawawa K., Okada M. Effects of intestinal bacteria on the development of colonic neoplasm: an experimental study. Eur. J. Cancer Prevent. 1999, 8:237-245.
43. Ellmerich S., Scholler M., Duranton B., Gossé F., Galluser M., Klein J.P., Raul F. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000, 21:753-756.
44. Newman J.V., Kosaka T., Sheppard B.J., Fox J.G., Schauer D.B. Bacterial infection promotes colon tumorigenesis in Apc (Min/+) mice. J. Infect. Dis. 2001, 184:227-230.
45. Maggio-Price L., Treuting P., Zeng W., Tsang M., Bielefeldt-Ohmann H., Iritani B.M. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer. Res. 2006, 66:828-838.
46. Moore W.E., Moore L.H. Intestinal floras of populations that have a high risk of colon cancer. Appl. Environ. Microbiol. 1995, 61:3202-3207.
47. Kanazawa K., Konishi F., Mitsuoka T., Terada A., Itoh K., Narushima S., Kumemura M., Kimura H. Factors influencing the development of sigmoid colon cancer: bacteriologic and biochemical studies. Cancer 1996, 77:1701-1706.
48. Tjalsma H., Schöller-Guinard M., Lasonder E., Ruers T.J., Willems H.L., Swinkels D.W. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int. J. Cancer 2006, 119:2127-2135.
49. Balamurugan R., Rajendiran E., George S., Samuel G.V., Ramakrishna B.S. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J. Gastroenterol. Hepatol. 2008, 23:1298-1303.
50. Scanlan P.D., Shanahan F., Clune Y., Collins J.K., O'Sullivan G.C., O'Riordan M., Holmes E., Wang Y., Marchesi J.R. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ. Microbiol. 2008, 10:789-798.
51. Seder C.W., Kramer M., Long G., Uzieblo M.R., Shanley C.J., Bove P. Clostridium septicum aortitis: report of two cases and review of the literature. J. Vasc. Surg. 2009, 49:1304-1309.
52. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., Brancati F.L., Wick E., McAllister F., Housseau F., Pardoll D.M., Sears C.L. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
53. Sobhani I., Tap J., Roudot-Thoraval F., Roperch J.P., Letulle S., Langella P., Corthier G., Van Nhieu J.T., Furet J.P. Microbial dysbiosis in colorectal cancer (CRC) patients. PloS One 2011, 6:e16393.
54. Nougayrède J.P., Oswald E. Microbiota and colorectal cancer: genotoxic bacteria in the intestinal tract. Bull. Acad. Natl. Med. 2011, 195:1295-1304.
55. Castellarin M., Warren R.L., Freeman J.D., Dreolini L., Krzywinski M., Strauss J., Barnes R., Watson P., Allen-Vercoe E., Moore R.A., Holt R.A. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome. Res. 2012, 22:299-306.
56. Wang T.T., Cai G.X., Qiu Y.P., Fei N., Zhang M.H., Pang X.Y., Jia W., Cai S.J., Zhao L.P. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME. J. 2012, 6:320-329.
57. Abdulamir A.S., Hafidh R.R., Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J. Exp. Clin. Cancer. Res. 2011, 30:11.
58. Gueimonde M., Ouwehand A., Huhtinen H., Salminen E., Salminen S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J. Gastroenterol. 2007, 13:3985-3989.
59. Shen X.J., Rawls J.F., Randall T., Burcal L., Mpande C.N., Jenkins N., Jovov B., Abdo Z., Sandler R.S., Keku T.O. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut. Microbes. 2010, 1:138-147.
60. Pagnini C., Corleto V.D., Mangoni M.L., Pilozzi E., Torre M.S., Marchese R., Carnuccio A., Giulio E.D., Delle Fave G. Alteration of local microflora and α-defensins hyper-production in colonic adenoma mucosa. J. Clin. Gastroenterol. 2011, 45:602-610.
61. Monleon D., Morales J.M., Barrasa A., Lopez J.A., Vazquez C., Celda B. Metabolite profling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009, 22:342-348.
62. Moreno A., Rey M., Montane J.M., Alonso J., Arus C. 1H NMR spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in tumors may have diagnostic significance. NMR Biomed. 1993, 6:111-118.
63. Moreno A., Arus C. Quantitative and qualitative characterization of 1H NMR spectra of colon tumors, normal mucosa and their perchloric acid extracts: decreased levels of myo-inositol in tumours can be detected in intact biopsies. NMR Biomed. 1996, 9:33-45.
64. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., Kinoshita T., Saito N., Ochiai A., Tomita M., Esumi H., Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69:4918-4925.
65. Chan E.C., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., Cavill R., Nicholson J.K., Keun H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome. Res. 2009, 8:352-361.
66. Denkert C., Budczies J., Weichert W., Wohlgemuth G., Scholz M., Kind T., Niesporek S., Noske A., Buckendahl A., Dietel M., Fiehn O. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008, 7:72.
67. Attene-Ramos M.S., Nava G.M., Muellner M.G., Wagner E.D., Plewa M.J., Gaskins H.R. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ. Mol. Mutagen. 2010, 51:304-314.
68. Christl S.U., Gibson G.R., Cummings J.H. Role of dietary sulphate in the regulation of methanogenesis in the human large intestine. Gut 1992, 33:1234-1238.
69. Ramasamy S., Singh S., Taniere P., Langman M.J., Eggo M.C. Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation. Am. J. Physiol. Gastrointest. Liver. Physiol. 2006, 291:G288-G296.
70. Hope M.E., Hold G.L., Kain R., El-Omar E.M. Sporadic colorectal cancer - role of the commensal microbiota. FEMS Microbiol. Lett. 2005, 244:1-7.
71. Handa O., Naito Y., Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox. Rep. 2011, 16:1-7.
72. Acharya A., Das I., Chandhok D., Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev. 2010, 3:23-34.
73. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51:794-798.
74. Ridlon J.M., Kang D.J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. J. Lipid. Res. 2006, 47:241-259.
75. Payne C.M., Crowley-Skillicorn C., Bernstein C., Holubec H., Moyer M.P., Bernstein H. Hydrophobic bile acid-induced micronuclei formation, mitotic perturbations, and decreases in spindle checkpoint proteins: Relevance to genomic instability in colon carcinogenesis. Nutr. Cancer 2010, 62:825-840.
76. Azcárate-Peril M.A., Sikes M., Bruno-Bárcena J.M. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?. Am. J. Physiol. Gastrointest. Liver. Physiol. 2011, 301:G401-G424.
77. Chang C.L., Marra G., Chauhan D.P., Ha H.T., Chang D.K., Ricciardiello L., Randolph A., Carethers J.M., Boland C.R. Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell. Physiol. 2002, 283:C148-C154.
78. Bernstein C., Holubec H., Bhattacharyya A.K., Nguyen H., Payne C.M., Zaitlin B., Bernstein H. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 2011, 85:863-871.
79. Imray C.H.E., Radley S., Davis A. Faecal unconjugated bile acids in patients with colorectal cancer or polyps. Gut 1992, 33:1239-1245.
80. Loh Y.H., Jakszyn P., Luben R.N., Mulligan A.A., Mitrou P.N., Khaw K.T. N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC) - Norfolk Study. Am. J. Clin. Nutr. 2011, 5:1053-1061.
81. Seitz H.K., Becker P. Alcohol metabolism and cancer risk. Alcohol. Res. Health 2007, 30:38-41.
82. Takada H., Hirooka T., Hiramatsu Y., Yamamoto M. Effect of beta-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats. Cancer Res. 1982, 42:331-334.
83. Dabek M., McCrae S.I., Stevens V.J., Duncan S.H., Louis P. Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 2008, 66:487-495.
84. Kim D.H., Jin Y.H. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. Arch. Pharm. Res. 2001, 24:564-567.
85. Bernstein C., Nfonsam V., Prasad A.R., Bernstein H. Epigenetic field defects in progression to cancer. World J. Gastrointest. Oncol. 2013, 15:43-49.
86. Schnekenburger M., Diederich M. Epigenetics offer new horizons for colorectal cancer prevention. Curr. Colorectal. Cancer. Rep. 2012, 8:66-81.
87. Balaguer F., Link A., Lozano J.J., Cuatrecasas M., Nagasaka T., Boland C.R., Goel A. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010, 70:6609-6618.
88. Singh N., Shirdel E.A., Waldron L., Zhang R.H., Jurisica I., Comelli E.M. The murine caecal microRNA signature depends on the presence of the endogenous microbiota. Int. J. Biol. Sci. 2012, 8:171-186.
89. Xue X., Feng T., Yao S., Wolf K.J., Liu C.G., Liu X., Elson C.O., Cong Y. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. J. Immunol. 2011, 187:5879-5886.
90. Raisch J., Darfeuille-Michaud A., Nguyen H.T. Role of microRNAs in the immune system inflammation and cancer. World J. Gastroenterol. 2013, 19:2985-2996.
91. Hu S., Dong T.S., Dalal S.R., Wu F., Bissonnette M., Kwon J.H., Chang E.B. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 2011, 6:e16221.
92. Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can. J. Gastroenterol. 2012, 26:909-915.
93. Fukata M., Abreu M.T. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27:234-243.
94. Davis C.D., Milner J.A. Gastrointestinal microflora, food components and colon cancer prevention. J. Nutr. Biochem. 2009, 20:743-752.
95. Sepulveda A.R., Yao Y., Yan W., Park D.I., Kim J.J., Gooding W., Abudayyeh S., Graham D.Y. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology 2010, 138:1836-1844.
96. Guo X.B., Guo L., Zhi Q.M., Ji J., Jiang J.L., Zhang R.J., Zhang J.N., Zhang J., Chen X.H., Cai Q., Li J.F., Yan M., Gu Q.L., Liu B.Y., Zhu Z.G., Yu Y.Y. Helicobacter pylori induces promoter hypermethylation and downregulates gene expression of IRX1 transcription factor on human gastric mucosa. J. Gastroenterol. Hepatol. 2011, 26:1685-1690.
97. Food and Agriculture Organization for the Unites Nations/World Health Organization. Probiotics in Food, Health and nutritional properties and guidelines for evaluation, FAO Food and Nutrition Paper 85, FAO, Rome (2006).
98. Fotiadis C.I., Stoidis C.N., Spyropoulos B.G., Zografos E.D. Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J. Gastroenterol. 2008, 14:6453-6457.
99. Roberfroid M., Gibson G.R., Hoyles L., McCartney A.L., Rastall R., Rowland I., Wolvers D., Watzl B., Szajewska H., Stahl B., Guarner F., Respondek F., Whelan K., Coxam V., Davicco M.J., Léotoing L., Wittrant Y., Delzenne N.M., Cani P.D., Neyrinck A.M., Meheust A. Prebiotic effects: metabolic and health benefits. Br. J. Nutr. 2010, 104(Suppl. 2):S1-63.
100. Geier M.S., Butler R.N., Howarth G.S. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer?. Cancer Biol. Ther. 2006, 5:1265-1269.
101. Liong M.T. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int. J. Mol. Sci. 2008, 9:854-863.
102. Zhu Y., Michelle Luo T., Jobin C., Young H.A. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett. 2011, 309:119-127.
103. Uccello M., Malaguarnera G., Basile F., D'Agata V., Malaguarnera M., Bertino G., Vacante M., Drago F., Biondi A. Potential role of probiotics on colorectal cancer prevention. BMC Surg. 2012, 12:S35.
104. Peitsidou K., Karantanos T., Theodoropoulos G.E. Probiotics, prebiotics, synbiotics: is there enough evidence to support their use in colorectal cancer surgery?. Dig. Surg. 2012, 29:426-438.
105. Goldin B.R., Swenson L., Dwyer J., Sexton M., Gorbach S.L. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J. Natl. Cancer Inst. 1980, 64:255-261.
106. Kato I., Kobayashi S., Yokokura T., Mutai M. Antitumor activity of Lactobacillus casei in mice. Gann 1981, 72:517-523.
107. Shackelford L.A., Rao D.R., Chawan C.B., Pulusani S.R. Effect of feeding fermented milk on the incidence of chemically induced colon tumors in rats. Nutr. Cancer 1983, 5:159-164.
108. Reddy B.S., Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo(4,5-f)quinoline, a food mutagen. Cancer Res. 1993, 53:3914-3918.
109. Kulkarni N., Reddy B.S. Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc. Soc. Exp. Biol. Med. 1994, 207:278-283.
110. Abdelali H., Cassand P., Soussotte V., Daubeze M., Bouley C., Narbonne J.F. Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Nutr. Cancer 1995, 24:121-132.
111. Gallaher D.D., Stallings W.H., Blessing L.L., Busta F.F., Brady L.J. Probiotics, cecal microflora, and aberrant crypts in the rat colon. J. Nutr. 1996, 126:1362-1371.
112. Pool-Zobel B.L., Neudecker C., Domizlaff I., Ji S., Schillinger U., Rumney C., Moretti M., Vilarini I., Scassellati-Sforzolini R., Rowland I. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr. Cancer 1996, 26:365-380.
113. Goldin B.R., Gualtieri L.J., Moore R.P. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr. Cancer 1996, 25:197-204.
114. Arimochi H., Kinouchi T., Kataoka K., Kuwahara T., Ohnishi Y. Effect of intestinal bacteria on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Biochem. Biophys. Res. Commun. 1997, 238:753-757.
115. Challa A., Rao D.R., Chawan C.B., Shackelford L. Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 1997, 18:517-521.
116. Singh J., Rivenson A., Tomita M., Shimamura S., Ishibashi N., Reddy B.S. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997, 18:833-841.
117. Rowland I.R., Rumney C.J., Coutts J.T., Lievense L.C. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998, 19:281-285.
118. McIntosh G.H., Royle P.J., Playne M.J. A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr. Cancer 1999, 35:153-159.
119. Rao C.V., Sanders M.E., Indranie C., Simi B., Reddy B.S. Prevention of colonic preneoplastic lesions by the probiotic Lactobacillus acidophilus NCFMTM in F344 rats. Int. J. Oncol. 1999, 14:939-944.
120. Yamazaki K., Tsunoda A., Sibusawa M., Tsunoda Y., Kusano M., Fukuchi K., Yamanaka M., Kushima M., Nomoto K., Morotomi M. The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. Oncol. Rep. 2000, 7:977-982.
121. Bolognani F., Rumney C.J., Pool-Zobel B.L., Rowland I.R. Effect of lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats. Eur. J. Nutr. 2001, 40:293-300.
122. Femia A.P., Luceri C., Dolara P., Giannini A., Biggeri A., Salvadori M., Clune Y., Collins K.J., Paglierani M., Caderni G. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002, 23:1953-1960.
123. Caderni G., Femia A.P., Giannini A., Favuzza A., Luceri C., Salvadori M., Dolara P. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 2003, 63:2388-2392.
124. Horie H., Zeisig M., Hirayama K., Midtvedt T., Moller L., Rafter J. Probiotic mixture decreases DNA adduct formation in colonic epithelium induced by the food mutagen 2-amino-9H-pyrido(2,3-b)indole in a human-flora associated mouse model. Eur. J. Cancer Prev. 2003, 12:101-107.
125. Roller M., Femia P.A., Caderni G., Rechkemmer G., Watzl B. Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br. J. Nutr. 2004, 92:931-938.
126. Le Leu R.K., Brown I.L., Hu Y., Bird A.R., Jackson M., Esterman A., Young G.P. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J. Nutr. 2005, 135:996-1001.
127. Park E., Jeon G.I., Park J.S., Paik H.D. A probiotic strain of Bacillus polyfermenticus reduces DMH induced precancerous lesions in F344 male rat. Biol. Pharm. Bull. 2007, 30:569-574.
128. A. de Moreno de LeBlanc, J.G. LeBlanc, G. Perdigon, A. Miyoshi, P. Langella, V. Azevedo and F. Sesma, Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice, J. Med. Microbiol. 57, 2008, 100-105.
129. Purohit D.H., Hassan A.N., Bhatia E., Zhang X., Dwivedi C. Rheological, sensorial, and chemopreventive properties of milk fermented with exopolysaccharide-producing lactic cultures. J. Dairy. Sci. 2009, 92:847-856.
130. Kumar A., Singh N.K., Sinha P.R. Inhibition of 1,2-dimethylhydrazine induced colon genotoxicity in rats by the administration of probiotic curd. Mol. Biol. Rep. 2009, 37:1373-1376.
131. Kumar A., Singh N.K., Sinha P.R., Kumar R. Intervention of Acidophilus-casei dahi and wheat bran against molecular alteration in colon carcinogenesis. Mol. Biol. Rep. 2010, 37:621-627.
132. Le Leu R.K., Hu Y., Brown I.L., Woodman R.J., Young G.P. Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Carcinogenesis 2010, 31:246-251.
133. Appleyard C.B., Cruz M.L., Isidro A.A., Arthur J.C., Jobin C., De Simone C. Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am. J. Physiol. Gastrointest. Liver. Physiol. 2011, 6:G1004-1013.
134. Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Hontecillas R. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One 2012, 7:e34676.
135. Kumar R.S., Kanmani P., Yuvaraj N., Paari K.A., Pattukumar V., Thirunavukkarasu C., Arul V. Lactobacillus plantarum AS1 isolated from south Indian fermented food Kallappam suppress 1,2-dimethyl hydrazine (DMH)-induced colorectal cancer in male Wistar rats. Appl. Biochem. Biotechnol. 2012, 166:620-631.
136. Friedenreich C.M., Brant R.F., Riboli E. Influence of methodologic factors in a pooled analysis of 13 case-control studies of colorectal cancer and dietary fiber. Epidemiology 1994, 5:66-79.
137. Hughes R., Rowland I.R. Stimulation of apoptosis by two prebiotic chicory fructans in the rat colon. Carcinogenesis 2001, 22:43-47.
138. Buddington K.K., Donahoo J.B., Buddington R.K. Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. J. Nutr. 2002, 132:472-477.
139. Ghoneum M., Abedi S. Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). J. Pharm. Pharmacol. 2004, 56:1581-1588.
140. Bauer-Marinovic M., Florian S., Muller-Schmehl K., Glatt H., Jacobasch G. Dietary resistant starch type 3 prevents tumor induction by 1,2-dimethylhydrazine and alters proliferation, apoptosis and dedifferentiation in rat colon. Carcinogenesis 2006, 27:1849-1859.
141. Hatakka K., Holma R., El-Nezami H., Suomalainen T., Kuisma M., Saxelin M., Poussa T., Mykkanen H., Korpela R. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int. J. Food. Microbiol. 2008, 128:406-410.
142. Worthley D.L., Le Leu R.K., Whitehall V.L., Conlon M., Christophersen C., Belobrajdic D., Mallitt K.A., Hu Y., Irahara N., Ogino S., Leggett B.A., Young G.P. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am. J. Clin. Nutr. 2009, 90:578-586.
143. Ohara T., Yoshino K., Kitajima M. Possibility of preventing colorectal carcinogenesis with probiotics. Hepatogastroenterology 2010, 57:1411-1415.
144. Ishikawa H., Akedo I., Otani T., Suzuki T., Nakamura T., Takeyama I., Ishiguro S., Miyaoka E., Sobue T., Kakizoe T. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int. J. Cancer 2005, 116:762-767.
145. Rafter J., Bennett M., Caderni G., Clune Y., Hughes R., Karlsson P.C., Klinder A., O'Riordan M., O'Sullivan G.C., Pool-Zobel B., Rechkemmer G., Roller M., Rowland I., Salvadori M., Thijs H., Van Loo J., Watzl B., Collins J.K. Dietary synbiotics reduce cancer risk factors in polypectomised and colon cancer patients. Am. J. Clin. Nutr. 2007, 85:488-496.
146. Roller M., Clune Y., Collins K., Rechkemmer G., Watzl B. Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br. J. Nutr. 2007, 97:676-684.
147. Gianotti L., Morelli L., Galbiati F., Rocchetti S., Coppola S., Beneduce A., Gilardini C., Zonenschain D., Nespoli A., Braga M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J. Gastroenterol. 2010, 16:167-175.
148. Zhang J.W., Du P., Chen D.W., Cui L., Ying C.M. Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer. Zhonghua. Wei. Chang. Wai. Ke. Za. Zhi. 2010, 13:40-43.
149. Zhang J.W., Du P., Gao J., Yang B.R., Fang W.J., Ying C.M. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am. J. Med. Sci. 2012, 343:199-205.
150. Liu Z., Qin H., Yang Z., Xia Y., Liu W., Yang K., Jiang Y., Zhang H., Wang Y., Zheng Q. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study. Aliment. Pharmacol. Ther. 2011, 33:50-63.
151. Zhu D., Chen X., Wu J., Ju Y., Feng J., Lu G., Ouyang M., Ren B., Li Y. Effect of peri-operative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer. Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao. 2012, 32:1190-1193.
152. Liu Z.H., Huang M.J., Zhang X.W., Wang L., Huang N.Q., Peng H., Lan P., Peng J.S., Yang Z., Xia Y., Liu W.J., Yang J., Qin H.L., Wang J.P. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am. J. Clin. Nutr. 2013, 1:117-126.
153. Osterlund P., Ruotsalainen T., Korpela R., Saxelin M., Ollus A., Valta P., Kouri M., Elomaa I., Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomized study. Br. J. Cancer 2007, 97:1028-1034.
154. Delia P., Sansotta G., Donato V., Messina G., Frosina P., Pergolizzi S., de Renzis C. Prophylaxis of diarrhea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience. Dig. Liver. Dis. 2002, 34:S84-S86.
155. Delia P., Sansotta G., Donato V., Frosina P., Messina G., de Renzis C., Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 2007, 13:912-915.
156. Ohigashi S., Hoshino Y., Ohde S., Onodera H. Functional outcome, quality of life, and efficacy of probiotics in postoperative patients with colorectal cancer. Surg. Today 2011, 41:1200-1206.
157. Pala V., Sieri S., Berrino F., Vineis P., Sacerdote C., Palli D., Masala G., Panico S., Mattiello A., Tumino R., Giurdanella M.C., Agnoli C., Grioni S., Krogh V. Yogurt consumption and risk of colorectal cancer in the italian EPIC cohort. Int. J. Cancer 2011, 129:2712-2719.
158. Tanaka K., Yano M., Motoori M., Kishi K., Miyashiro I., Ohue M., Ohigashi H., Asahara T., Nomoto K., Ishikawa O. Impact of perioperative administration of synbiotics in patients with esophageal cancer undergoing esophagectomy: a prospective randomized controlled trial. Surgery 2012, 152:832-842.
159. O'Mahony L., Feeney M., O'Halloran S., Murphy L., Kiely B., Fitzgibbon J., Lee G., O'Sullivan G., Shanahan F., Collins J.K. Probiotic impact on microbial flora, inflammation and tumor development in IL-10 knockout mice. Aliment. Pharmacol. Ther. 2001, 15:1219-1225.
160. Sreekumar O., Hosono A. The antimutagenic properties of a polysaccharide produced by Bifidobacterium longum and its cultured milk against some heterocyclic amines. Can. J. Microbiol. 1998, 44:1029-1036.
161. Sreekumar O., Hosono A. The heterocyclic amine binding receptors of Lactobacillus gasseri cells. Mutat. Res. 1998, 421:65-72.
162. Stein K., Borowicki A., Scharlau D., Schettler A., Scheu K., Obst U., Glei M. Effects of synbiotic fermentation products on primary chemoprevention in human colon cells. J. Nutr. Biochem. 2012, 23:777-784.
163. Orrhage K.M., Annas A., Nord C.E., Brittebo E.B., Rafter J.J. Effects of lactic acid bacteria on the uptake and distribution of the food mutagen Trp-P-2 in mice. Scand. J. Gastroenterol. 2002, 37:215-221.
164. Kim Y., Lee D., Kim D., Cho J., Yang J., Chung M., Kim K., Ha N. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch. Pharm. Res. 2008, 31:468-473.
165. Goldin B.R., Gorbach S.L. The effect of milk and lactobacillus feeding on human intestinal bacterial enzyme activity. Am. J. Clin. Nutr. 1984, 39:756-761.
166. Spanhaak S., Havenaar R., Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microfora and immune parameters in humans. Eur. J. Clin. Nutr. 1998, 52:899-907.
167. Ghoneum M., Hamilton J., Brown J., Gollapudi S. Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer Res. 2005, 25:981-989.
168. Takagi A., Ikemura H., Matsuzaki T., Sato M., Nomoto K., Morotomi M., Yokokura T. Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. J. Gastroenterol. 2008, 43:661-669.
169. Lee J.W., Shin J.G., Kim E.H., Kang H.E., Yim I.B., Kim J.Y., Joo H.G., Woo H.J. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifdobacterium longum. J. Vet. Sci. 2004, 5:41-48.
170. Perdigon G., Maldonado Galdeano C., Valdez J.C., Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur. J. Clin. Nutr. 2002, 56(Suppl 4):S21-S26.
171. Pagnini C., Saeed R., Bamias G., Arseneau K.O., Pizarro T.T., Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc. Natl. Acad. Sci. USA 2010, 107:454-459.
172. Ohkawara S., Furuya H., Nagashima K., Asanuma N., Hino T. Effect of oral administration of Butyrivibrio fibrisolvens MDT-1, a gastrointestinal bacterium, on 3-methylcholanthrene-induced tumor in mice. J. Nutr. 2005, 135:2878-2883.
173. W. Han, A. Mercenier, A. Ait-Belgnaoui, S. Pavan, F. Lamine, M. van, S. Kleerebezem 2nd, C. Salvador-Cartier, M. Hisbergues, L. Bueno, V. Theodorou and J. Fioramonti, Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase, Inflamm. Bowel. Dis. 12, 2006, 1044-1052.
174. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., Klaenhammer T.R., Hassan H.M., Threadgill D.S. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am. J. Physiol. Gastrointest. Liver. Physiol. 2007, 293:G729-G738.
175. Jan G., Belzacq A.S., Haouzi D., Rouault A., Metivier D., Kroemer G., Brenner C. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell. Death. Differ. 2002, 9:179-188.
176. Ewaschuk J.B., Walker J.W., Diaz H., Madsen K.L. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J. Nutr. 2006, 136:1483-1487.
177. Lidbeck A., Geltner-Allinger U., Orrhage K.M., Ottova L., Brismar B., Gustafson J., Rafter J.J., Nord C.E. Impact of Lactobacillus acidophilus supplements on the fecal microflora and soluble fecal bile acids in colon cancer patients. Microb. Ecol. Health Dis. 1991, 4:81-88.
178. Biasco G., Paganelli G.M., Brandi G., Brillanti S., Lami F., Callegari C., Gizzi G. Effect of lactobacillus acidophilus and bifdobacterium bifdum on rectal cell kinetics and fecal pH. Ital. J. Gastroenterol. 1991, 23:142.
179. Orlando A., Messa C., Linsalata M., Cavallini A., Russo F. Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol. Immunotoxicol. 2009, 31:108-116.
180. Linsalata M., Cavallini A., Messa C., Orlando A., Refolo M.G., Russo F. Lactobacillus rhamnosus GG influences polyamine metabolism in HGC-27 gastric cancer cell line: a strategy toward nutritional approach to chemoprevention of gastric cancer. Curr. Pharm. Des. 2010, 16:847-853.
181. Linsalata M., Russo F., Berloco P., Valentini A.M., Caruso M.L., De Simone C., Barone M., Polimeno L., Di Leo A. Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. In Vivo 2005, 19:989-995.
182. Orlando A., Refolo M.G., Messa C., Amati L., Lavermicocca P., Guerra V., Russo F. Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2.1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutr. Cancer 2012, 64:1103-1111.
183. Lee N.K., Park J.S., Park E., Paik H.D. Adherence and anticarcinogenic effects of Bacillus polyfermenticus SCD in the large intestine. Lett. Appl. Microbiol. 2007, 44:274-278.
184. Iyer C., Kosters A., Sethi G., Kunnumakkara A.B., Aggarwal B.B., Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signaling. Cell. Microbiol. 2008, 10:1442-1452.
185. Otte J.M., Mahjurian-Namari R., Brand S., Werner I., Schmidt W.E., Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr. Cancer 2009, 61:103-113.
186. Baldwin C., Millette M., Oth D., Ruiz M.T., Luquet F.M., Lacroix M. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr. Cancer 2010, 62:371-378.
187. Cousin F.J., Jouan-Lanhouet S., Dimanche-Boitrel M.T., Corcos L., Jan G. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One 2012, 3:e31892.
188. Urbanska A.M., Bhathena J., Martoni C., Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc(Min/+) mice. Dig. Dis. Sci. 2009, 54:264-273.
189. Baricault L., Denariaz G., Houri J.J., Bouley C., Sapin C., Trugnan G. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis 1995, 16:245-252.
190. Grimoud J., Durand H., de Souza S., Monsan P., Ouarné F., Theodorou V., Roques C. In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int. J. Food. Microbiol. 2010, 144:42-50.
191. Thirabunyanon M., Hongwittayakorn P. Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells via synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. Appl. Biochem. Biotechnol. 2013, 168:511-525.
192. Chen X., Fruehauf J., Goldsmith J.D., Xu H., Katchar K.K., Koon H.W., Zhao D., Kokkotou E.G., Pothoulakis C., Kelly C.P. Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 2009, 137:914-923.
193. Ma E.L., Choi Y.J., Choi J., Pothoulakis C., Rhee S.H., Im E. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int. J. Cancer 2002, 127:780-790.
194. Escamilla J., Lane M.A., Maitin V. Cell-free supernatants from probiotic Lactobacillus casei and Lactobacillus rhamnosus GG decrease colon cancer cell invasion in vitro. Nutr. Cancer 2012, 6:871-878.
195. Rhee C.H., Park H.D. Three glycoproteins with antimutagenic activity identified in Lactobacillus plantarum KLAB21. Appl. Environ. Microbiol. 2001, 67:3445-3449.
196. Maze A., Boel G., Zuniga M., Bourand A., Loux V., Yebra M.J., Monedero V., Correia K., Jacques N., Beaufils S., Poncet S., Joyet P., Milohanic E., Casaregola S., Auffray Y., Perez-Martinez G., Gibrat J.F., Zagorec M., Francke C., Hartke A., Deutscher J. Complete genome sequence of the probiotic Lactobacillus casei strain BL23. J. Bacteriol. 2010, 192:2647-2648.
197. Kim K.H., Park H.S. Dietary supplementation of conjugated linoleic acid reduces colon tumor incidence in DMH-treated rats by increasing apoptosis with modulation of biomarkers. Nutrition 2003, 19:772-777.